Aminothiazole inhibitors of cyclin dependent kinases
US6262096A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 15, 1999 |
| Grant date | Jul 17, 2001 |
| Priority date | — |
| Expiry date | Dec 15, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof. PA1 R.sub.1 and R.sub.2 are independently hydrogen, fluorine or alkyl; PA1 R.sub.3 is aryl or heteroaryl PA1 R.sub.4 is alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl; PA1 m is an integer of 0 to 2; and PA1 n is an integer of 1 to 3. The compounds of formula I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.